Research To Practice | Oncology Videos

Latest Episodes:

Chronic Lymphocytic Leukemia | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia Feb 27, 2024

Show notes

Featuring perspectives from Dr Lindsey Roeker and Dr Jeff Sharman, including the following topics:

An Audio Depiction of Mechanisms of Action of Bcl-2 Inhibitors, Anti-CD20 Antibodies and Covalent and Noncovalent Bruton Tyrosine Kinase Inhibitors; Mechanisms of Resistance (0:00)
Current Management Approaches for Patients with Chronic Lymphocytic Leukemia (CLL) — Dr Sharman (12:27)
Future Directions in the Care of Patients with CLL — Dr Roeker (33:54)

CME information and select publications

Hepatobiliary Cancers | Consensus or Controversy? Investigator Perspectives on the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers Feb 23, 2024

Show notes

Featuring perspectives from Dr Ahmed Omar Kaseb and Prof Arndt Vogel, including the following topics:

Introduction: EMERALD-1 — Immune Checkpoint Inhibitor-Based Therapy for Localized HCC Eligible for Embolization (0:00)
Optimal Utilization of Immune Checkpoint Inhibitors as First-Line Therapy for Advanced HCC – Dr Kaseb (12:49)
Incorporation of Anti-PD-1/PD-L1 Antibody-Based Approaches for Advanced Biliary Tract Cancers (BTCs) — Prof Vogel (40:24)

CME information and select publications

Prostate Cancer | Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Prostate Cancer Feb 20, 2024

Show notes

Featuring perspectives from Dr Rahul Aggarwal, Dr Emmanuel S Antonarakis, Dr Elisabeth I Heath and Dr A Oliver Sartor, moderated by Dr Alan H Bryce, including the following topics:

Introduction (0:00)
Optimizing the Management of Nonmetastatic Prostate Cancer — Dr Aggarwal (1:51)
Evidence-Based Selection of Treatment for Metastatic Hormone-Sensitive Prostate Cancer — Dr Antonarakis (25:39)
New Considerations with PARP Inhibitors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Bryce (47:31)
Role of Novel Radiopharmaceuticals in Therapy for mCRPC — Dr Sartor (1:10:09)
Promising Investigational Approaches for Patients with Prostate Cancer — Dr Heath (1:32:05)

CME information and select publications

Ovarian Cancer | Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 4 of a 4-Part Series Feb 16, 2024

Show notes

Featuring perspectives from Dr Bradley J Monk, including the following topics:

Introduction (0:00)
Case: A woman (gBRCA1) in her late 40s, 5 months after surgery and adjuvant paclitaxel/carboplatin for Stage II ovarian cancer, now with a single umbilical metastasis — Kellie E Schneider, MD (9:47)
Case: A woman (gBRCA2) in her late 60s with Stage IIIC ovarian cancer after surgery and chemotherapy who has received primary olaparib maintenance for 3 years develops acute myeloid leukemia — Swati Vishwanathan, MD (17:21)
Case: A woman in her early 60s presents with Stage IV ovarian cancer (BRCA wild-type, homologous recombination deficiency-positive) — Neil Morganstein, MD (22:53)
Case: A woman (gBRCA2) in her late 40s with Stage IIIC primary peritoneal cancer receives carboplatin/paclitaxel after R0 debulking surgery; genetic testing results pending — Karim ElSahwi, MD (27:30)
Case: A woman in her early 60s with PMH of breast cancer and with limited recurrence of ovarian cancer (BRCA wild-type, homologous recombination deficiency-positive) after chemotherapy and maintenance niraparib refuses to receive chemotherapy — Gigi Chen, MD (33:06)
Case: A woman (gBRCA2) in her mid 60s with high-grade serous carcinoma of the fallopian tube undergoes surgery and chemotherapy/bevacizumab but cannot tolerate a PARP inhibitor and refuses to take another agent — Thomas P Morrissey, MD (40:51)
Case: A woman (homologous repair deficiency-positive) in her mid 70s with ovarian cancer and disease progression on EPIK-O trial of alpelisib with olaparib tests positive for folate receptor alpha and receives mirvetuximab soravtansine — Lyndsay J Willmott, MD (45:46)
Journal Club with Dr Monk (54:13)

CME information and select publications

Colorectal Cancer | Consensus or Controversy? Clinical Investigators Provide Perspectives on Biomarker Assessment and Related Treatment Decision-Making for Patients with Colorectal Cancer Feb 15, 2024

Show notes

Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Andrea Cercek, Dr Cathy Eng and Dr John Strickler, moderated by Dr Christopher Lieu, including the following topics:

Introduction (0:00)
Optimizing Biomarker Assessment and Treatment for Patients with Metastatic Colorectal Cancer (mCRC) — Dr Eng (2:48)
Emerging Role of Biomarker-Based Decision-Making for Patients with Localized CRC — Dr Lieu (28:14)
Identification and Clinical Care of Patients with mCRC and a BRAF V600E Mutation — Dr Bekaii-Saab (51:20)
Integration of Immune Checkpoint Inhibitors into the Management of Microsatellite Instability-High/Mismatch Repair-Deficient mCRC — Dr Cercek (1:14:34)
HER2 and Other Emerging Biomarkers for Targeted Therapy in mCRC — Dr Strickler (1:35:48)

CME information and select publications

Urothelial Bladder Cancer | Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Urothelial Bladder Cancer Feb 09, 2024

Show notes

Featuring perspectives from Dr Matthew Milowsky, Dr Peter H O'Donnell, Dr Jonathan E Rosenberg and Dr Arlene Siefker-Radtke, moderated by Dr Evan Y Yu, including the following topics:

Introduction (0:00)
Role of Anti-PD-1/PD-L1 Antibodies in Therapy for Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Milowsky (2:54)
Other Novel Strategies Under Investigation for Nonmetastatic UBC — Dr O'Donnell (25:53)
Front-Line Treatment for Metastatic UBC (mUBC) — Dr Rosenberg (49:43)
Emerging Role of HER2-Targeted Therapy for mUBC — Dr Yu (1:12:03)
Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Dr Siefker-Radtke (1:35:51)

CME information and select publications

Gastroesophageal Cancers | Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Gastroesophageal Cancers Feb 07, 2024

Show notes

Featuring perspectives from Dr David H Ilson, Dr Rutika Mehta, Dr Markus Moehler and Dr Manish A Shah, moderated by Dr Harry H Yoon, including the following topics:

Introduction (0:00)
Recent Developments in the Management of Localized or Locally Advanced Gastroesophageal Cancers — Dr Ilson (2:02)
Incorporation of First-Line Immunotherapeutic Strategies for Patients with Metastatic Gastroesophageal Tumors — Dr Yoon (26:40)
Emerging Role of Therapy Targeting Claudin 18.2 in Advanced Gastric/GEJ Adenocarcinoma — Dr Shah (50:10)
Current Considerations in the Care of Patients with HER2-Positive Gastroesophageal Cancers — Dr Moehler (1:13:14)
Selection and Sequencing of Therapy for Patients with Relapsed/Refractory (R/R) HER2-Negative Gastroesophageal Cancers — Dr Mehta (1:34:54)

CME information and select publications

Hormone Receptor-Positive Breast Cancer | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast Cancer Feb 01, 2024

Show notes

Featuring perspectives from Dr Stephanie L Graff and Dr Erica Mayer, including the following topics:

Introduction: Endocrinology and Pharmacology of Hormonal Therapy for Breast Cancer (0:00)
Current and Emerging Strategies for Localized Hormone Receptor (HR)-Positive Breast Cancer — Dr Graff (17:02)
Advances in the Care of Patients with HR-Positive Metastatic Breast Cancer — Dr Mayer (38:59)

CME information and select publications

Hormone Receptor-Positive Breast Cancer | Erica Mayer, MD, MPH, FASCO Feb 01, 2024

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast Cancer | Faculty Presentation 2: Relevant Advances in the Care of Patients with HR-Positive Metastatic BC (mBC) — Erica Mayer, MD, MPH, FASCO

CME information and select publications

Hormone Receptor-Positive Breast Cancer | Stephanie L Graff, MD, FACP Feb 01, 2024

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast Cancer | Faculty Presentation 1: Current and Emerging Strategies for Early-Stage HR-Positive Breast Cancer (BC) — Stephanie L Graff, MD, FACP

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected